Quick Answer
Kalaris Therapeutics, Inc. reported Net Income of -$43.44 million for fiscal year 2025.
Kalaris Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$43.44M | +37.2% |
| 2024 | -$69.17M | +63.7% |
| 2023 | -$190.42M | -12.9% |
| 2022 | -$168.71M | +1.9% |
| 2021 | -$171.96M | -146.4% |
| 2020 | -$69.78M | -192.7% |
| 2019 | -$23.84M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.89M | +68.8% | -4.8% |
| June 30, 2025 | -$11.35M | -100.9% | -11.3% |
| March 31, 2025 | -$10.20M | -199.3% | +73.2% |
| September 30, 2024 | -$38.08M | +14.0% | -574.1% |
| June 30, 2024 | -$5.65M | +87.5% | -65.8% |
| March 31, 2024 | -$3.41M | +91.7% | +92.3% |
| September 30, 2023 | -$44.27M | -5.2% | +2.2% |
| June 30, 2023 | -$45.27M | -1.4% | -9.9% |
- Kalaris Therapeutics, Inc. showed an increase of +37.2% in Net Income compared to the prior fiscal year.
- Over the 2019–2025 period, Kalaris Therapeutics, Inc.’s net income has declined by 82.2% (from -$23.84 million to -$43.44 million).
- The most recent figure is from Kalaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: